|
Cocaine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice.
|
16339038 |
2005 |
|
Cocaine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice.
|
16339038 |
2005 |
|
Cocaine Dependence
|
0.300 |
Biomarker
|
disease |
CTD_human |
Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice.
|
16339038 |
2005 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.
|
29304378 |
2018 |
|
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density.
|
24249740 |
2014 |
|
Bone Mineral Density Test
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.
|
22504420 |
2012 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MSK1 prevents metastatic progression of ER<sup>+</sup> breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK1 expression could improve prognosis.
|
29358704 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
This association between high MSK1 expression and improved breast cancer-specific survival was observed in the whole cohort (P = 0.009) and in the HER2-negative and non-basal like tumours (P = 0.006 and P = 0.024, respectively).
|
29327245 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancer.
|
29674681 |
2018 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
This association between high MSK1 expression and improved breast cancer-specific survival was observed in the whole cohort (P = 0.009) and in the HER2-negative and non-basal like tumours (P = 0.006 and P = 0.024, respectively).
|
29327245 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancer.
|
29674681 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MSK1 prevents metastatic progression of ER<sup>+</sup> breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK1 expression could improve prognosis.
|
29358704 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor.
|
23604116 |
2014 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor.
|
23604116 |
2014 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
In patients with ER<sup>+</sup> breast cancer, low MSK1 expression associates with early metastasis.
|
29358704 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Low MSK1 protein expression was significantly associated with shorter time to distant metastasis (P < 0.001), and recurrence (P = 0.013) and early death due to breast cancer (P = 0.01).
|
29327245 |
2018 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Low MSK1 protein expression was associated with younger age (P = 0.004), higher tumour grade (P < 0.001), higher Nottingham Prognostic Index scores (P = 0.007), negative ER (P < 0.001) and PR (P < 0.001) status, and with triple-negative (P < 0.001) and basal-like (P < 0.001) phenotypes.
|
29327245 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the involvement of MSK1 in malignant transformation and cancer development is not well understood.
|
25958199 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the involvement of MSK1 in malignant transformation and cancer development is not well understood.
|
25958199 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In both MDA435 wild type (WT) and MDA435 resistant (R) xenografts in nude mice, double silencing of Mcl-1/RPS6KA5 also led to improved inhibition of tumor growth in the absence of chemotherapy.
|
23994345 |
2013 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
This review proposes that MSK1/2 is an optimal target for cancer therapy, based on its fundamental role in transmitting external signals into varied responses involved in cancer development.
|
22250664 |
2012 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
This review proposes that MSK1/2 is an optimal target for cancer therapy, based on its fundamental role in transmitting external signals into varied responses involved in cancer development.
|
22250664 |
2012 |
|
Primary Sjögren's syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> The decreased expression of miR-130a and miR-708 in pSS cDC2s seems to reflect cell activation. miR-130a targets MSK1, which regulates pro-inflammatory cytokine production, and we provide proof-of-concept for MSK1-inhibition as a therapeutic avenue to impede cDC2 activity in pSS.
|
31281310 |
2019 |